MedTrace Logo

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intrathecal Injection for ALS

NCT05003921 · Status: SUSPENDED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-04-17

No results posted yet for this study

Summary

This trial will study the safety and efficacy of intrathecal injection of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of amyotrophic lateral sclerosis

Conditions

Interventions

BIOLOGICAL

AlloRx

cultured allogeneic adult umbilical cord derived mesenchymal stem cells

Sponsors & Collaborators

  • The Foundation for Orthopaedics and Regenerative Medicine

    lead OTHER

Principal Investigators

  • Chadwick Prodromos, MD · The Foundation for Orthopaedics and Regenerative Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-31
Primary Completion
2028-09-30
Completion
2028-09-30
FDA Drug
Yes

Countries

  • Antigua and Barbuda

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05003921 on ClinicalTrials.gov